Survival outcomes in HGBL-NOS based on the first-line therapy. (A) PFS among patients treated with R-CHOP, DA-EPOCH-R, R-CODOX-M/IVAC, or R-hyperCVAD/MA; P values compare R-CHOP with other (intensive) regimens; (B) PFS among patients treated with R-CHOP or DA-EPOCH-R, stratified based on the presence or absence of MYC rearrangement (MYC-R), P values compare MYC-R⁺ groups treated with R-CHOP or DA-EPOCH-R; (C) PFS among patients with Burkitt-like HGBL-NOS (excluding transformed and PTLD cases) treated with R-CHOP or DA-EPOCH-R; and (D-F) analogous curves for OS.